ERBB2 and breast cancer: Taking into consideration the heterogeneous properties of BC, we also evaluated the clinical value of CD_Score in predicting prognosis among different subgroups (age, molecular subtype, clinical stage, hormone receptor, and HER2 status) and further confirmed the role of CD_Score as a robust prognostic biomarker (Figure S9).